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Background: The population of patients with human epidermal growth factor receptor 2 (HER2)-positive breast
cancer (BC) who develop central nervous system (CNS) metastases is growing. Treatment strategies in this
population are highly diverse. The objective of the study was to assess health care costs for the management of
HER2 positive BC with CNS metastases.
Methods: This multicentre, retrospective, observational study was conducted on HER2-positive BC patients diag-
nosed with CNS metastases between 2006 and 2008. Data were extracted from patient medical records to estimate
health care resource use. A partitioned estimator was used to adjust censoring costs by use of the Kaplan-Meier sur-
vival estimate.
Results: 218 patients were included and costs were estimated for 200 patients. The median time to detection of
CNS metastases was 37.6 months. The first metastatic event involved the CNS in 39 patients, and this was the
unique first metastatic site in 31 of these patients. Two years following diagnosis of CNS metastases, 70.3% of
patients had died. The mean per capita cost of HER2-positive BC with CNS metastases in the first year following
diagnosis was €35,735 [95% CI: 31,716-39,898]. The proportion of costs attributed to expensive drugs and those
arising from hospitalisation were in the same range.
Conclusion: A range of individualised disease management strategies are used in HER2-positive BC patients with
CNS metastases and the treatments used in the first months following diagnosis are expensive. The understanding
of cost drivers may help optimise healthcare expenditure and inform the development of appropriate prevention
policies.
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In 2011, an estimated 53,000 new cases of breast cancer
(BC) were diagnosed and almost 11,500 women died
from BC in France [1]. About 5%-15% of new cases of
BC are diagnosed at the metastatic stage, when the esti-
mated five-year survival rate is 13% [1]. The apparent in-
cidence of central nervous system (CNS) metastases in
BC is increasing [2]. This may be due in part to improved
imaging and earlier detection of CNS lesions and in part
to the availability of more effective systemic treatments
that allow more patients to live long enough to develop
CNS metastases [3,4]. In general, survival for BC patients
with CNS metastases is poor, with one-year survival of
approximately 20% [2]. Compared with patients without
CNS metastases, patients with CNS metastases tend to
be younger and more likely to have hormone receptor-
negative disease and a higher disease burden [5,6].
Over-expression of the gene encoding human epider-
mal growth factor receptor 2 (HER2) plays an important
role in the pathogenesis of certain types of BC [7]. Positive
HER2 status is associated with poor prognosis and a higher
incidence of CNS metastases in BC. HER2-positive tu-
mours may have a biological predisposition to metastasise
within the CNS and about 40% of patients with brain me-
tastases reported in published case series have HER2-
positive BC [2,8]. However, despite these initial poor global
prognostic features, patients with HER2-positive disease
seem to have a better short-term prognosis at the onset of
CNS metastases than HER2-negative patients. The de-
velopment of anti-HER2 targeted therapies such as tras-
tuzumab and lapatinib combined with chemotherapy
has significantly improved survival in HER2-positive ad-
vanced BC patients [9-12]. Indeed, it has been shown
that combination of trastuzumab with standard chemo-
therapy is associated with significantly improved survival
following development of CNS metastases in BC patients
compared to patients receiving standard chemotherapy
only [5]. This has encouraged systematic screening of
HER2 status in patients with BC. In the case series above
[2,8], many patients were responding to trastuzumab or
had stable systemic disease when they developed brain
metastases. However, like many other targeted therapies
and cytotoxic chemotherapies, trastuzumab does not eas-
ily cross the intact blood–brain barrier [13]. This may lead
to sanctuarisation of CNS metastases within the nervous
system, allowing them to develop independently of the
quality of peripheral disease control.
The management of HER2-positive BC with CNS me-
tastases is based on diversified, non-standardised and
increasingly innovative and expensive pharmacological
treatments, including targeted therapies, as well as radio-
therapy and surgery [8,14]. The costs, risks and benefits of
such approaches remain poorly characterised. However,
healthcare cost assessment is necessary for such emerginginnovative and expensive targeted therapies, particularly
in the context of cost-containment initiatives imple-
mented by health authorities in many countries. For ex-
ample, in France, the recent Program of Social Security
funding emphasised the need for input from economic
studies to facilitate the decision process relating to reim-
bursement of health technologies.
Individual current cost data on HER2-positive BC with
CNS metastases are limited and published series have
mainly reported costs of advanced BC, regardless of
their subtype [15-17]. Economic data on healthcare costs
can be derived from several sources, including analysis
of prescription claims databases, observational studies of
patient cohorts and modelling approaches. Each approach
has its own advantages and limitations, although cohort
studies are thought to provide the most exhaustive infor-
mation, and represent the only approach that allows costs
to be matched to outcomes on an individual patient basis.
The objective of the present study was to describe
treatment patterns and health care costs associated with




We conducted a multicentre, retrospective, observational
study of HER2-positive BC patients diagnosed with CNS
metastases. All consecutive patients fulfilling the eligibility
criteria were included. Women with HER2-positive BC
who had been newly diagnosed with CNS metastases be-
tween January 2006 and December 2008 and who were
over 18 years of age were eligible. Patients with multiple
tumours were excluded. CNS metastases were classified as
initial site of relapse or as secondary metastases. Both me-
tastases in the brain parenchyma and leptomeningeal me-
tastases were considered as CNS metastases.
Study centres
Patients were recruited in ten French cancer centres,
selected according to their medical activity (number of
patients currently treated) and their compliance with
international guidelines for the management of BC and
determination of HER2 status [18]. The case-mix of cen-
tres was chosen to represent the current standard man-
agement of BC in France. In all participating centres,
healthcare was funded and reimbursed in the same stan-
dardised way though the prospective payment system of
the French National Health Service.
Patient selection
Patients were selected using the disease coding of the
ICD 10 (International Classification of Diseases, tenth
revision), which is systematically assigned to all patient re-
cords in French hospitals. Inpatient stays coded as breast
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Individual data concerning initial diagnosis, distant and
CNS relapses, treatments received and examinations per-
formed, clinical outcomes and complications following the
CNS event and admissions were collected. Data were col-
lected retrospectively from the hospital database and all
information relating to use of healthcare resources was
documented for the two years following the date of diag-
nosis of CNS metastases, or until death if this occurred
within two years.
Clinical outcomes
The clinical outcomes evaluated were overall survival
and time to reach Graded Prognostic Assessment (GPA)
scores [19-21] of 1–2, 2.5-3 and 3.5-4.
Identification and allocation of costs
Pricing of health services in France is determined at the
national level by a Prospective Payment System. Under
this system, the income of each hospital is linked directly
to the number and type of patients treated, classified in
terms of diagnosis-related groups (DRGs). The classifica-
tion system used in France was inspired by the US
Health Care Financing Group classification, but adapted
to the French healthcare system. Assignment of patients
to DRGs is based on the primary diagnosis. Data on age,
length of stay and mode of discharge (death, transfer)
are used to define case severity. The DRG prices (tariffs)
for each service are set annually based on average costs
and are applicable countrywide. In addition, a restricted
list of expensive drugs is reimbursed over and above
these standard tariffs.
In the present study, direct medical costs were esti-
mated from the French Health Insurance perspective on
the basis of DRG official tariffs and expensive innovative
drug tariffs. Costs were estimated from the total mean
dose received during each treatment course, the number
of courses and the mean price per dose. Costs were
expressed in Euros based on 2007 tariffs.
Statistical analysis
Socio-demographic and clinical variables were compared
using the χ2 test or Fisher’s exact test for categorical var-
iables and ANOVA or rank-ANOVA for continuous vari-
ables. Survival was estimated using the Kaplan-Meier
method and the log-rank test. Costs were described in
terms of mean values with confidence intervals. The stand-
ard deviation of the mean cost was estimated using the
Bootstrap resampling method. Since costs per treatment
cycle could be limited due to incomplete survival, these
costs were censored in order to estimate actual cost ex-
penditure as accurately as possible [22,23]. Costs were
adjusted by the Kaplan-Meier estimate for survival to gen-
erate a monthly cost, which was used to estimate totalcosts. All tests were two-sided with a limit of significance
of 5%. Data analyses were performed with the SAS soft-
ware (version 9.2, SAS Institute Inc, USA).
Ethics
This study was a retrospective observational study that
did not modify medical care for people entering the
study. For this reason, no written consent form or ethics
committee approval was required. Patients were notified
by newsletter that the study was being carried out. This
study protocol and access to individual patient data were
approved by the CCTIRS (Comité consultatif sur le trai-
tement de l’information en matière de recherche dans le
domaine de la santé, Authorisation N°10-111) and the
Commission Nationale Informatique et Libertés (CNIL:




A total of 218 patients were enrolled in the study and
direct medical costs were estimated on 200 patients for
whom exhaustive economic data and DRGs were avail-
able. The clinical characteristics of the 218 patients en-
rolled are presented in Table 1. Median age was 51 years
at the time of initial diagnosis of BC and 54 years at the
time of diagnosis of CNS metastases. The median time
to first metastatic relapse at any site was 21.9 months
(0–214.7). The median interval between BC diagnosis and
detection of CNS metastases was 37.6 months (0–286.5).
The initial metastatic event involved the CNS in 39 pa-
tients (17.4%), this being the unique first metastatic site in
31 patients. Carcinomatous meningitis was present in 28
patients (13%). Prior to diagnosis of CNS metastases, all
patients had received trastuzumab-based therapies and 21
had received lapatinib-based therapies.
Clinical outcomes
Median overall survival from diagnosis of CNS metastasis
was 13.1 (11–15.8) months (Figure 1). Two years after
diagnosis of CNS metastasis, 70.3% of patients had died
(Kaplan-Meier estimate). Death was due to progression of
CNS metastases (69.7%), distant metastases (12.7%), both
(9.3%) or other unspecified cause (8.1%). The median time
to reach GPA scores of 1–2, 2.5-3 and 3.5-4 was 10, 12 and
24 months respectively.
Health-care resources used after diagnosis of CNS
metastases
Complete data on resource utilisation were available for
200 patients. Table 2 presents the health-care resources
used after diagnosis of CNS metastases. Chemotherapy,
including targeted therapy, and radiotherapy were the
treatments most frequently used. Whenever significant
Table 1 Clinical characteristics of the study population (N = 218 patients)
Initial diagnosis
Median age at BC diagnosis (years, range) 51 (24-81)
Invasive ductal carcinoma (patients, %) 202/218 (92.7%)
Median tumour size (mm, range) 25 mm (1-200)*
Presence of lymph node involvement (evaluable tumours, %) 72/134 evaluable tumours (53.7%)
Oestrogen receptor-positive (patients, %) 93/192* (48.4%)
Progesterone receptor-positive (patients, %) 60/164* (36.6%)
Treatments before CNS metastases
Chemotherapy before CNS metastases (patients, %) 210/218 (96.3%)
HER2-targeted therapy before CNS metastases (patients, %) 197/218 (90.4%)
Bevacizumab before CNS metastases (patients, %) 3/218 (1.4%)
Hormone therapy before CNS metastases (patients, %) (ER and PR positive at initial diagnosis N = 110 patients) 82/110 (74.5%)
Local radiation therapy before CNS metastases (patients, %) 159/218 (72.9%)
Metastatic disease
Median time to first metastatic relapse, any site (months, range) 21.9 months (0-214.7)
Median time between initial BC diagnosis and CNS metastasis (months, range) 37.6 months (0-286.5)
Median time to first relapse and CNS metastasis (months, range) 12.9 months (0-283.7)
CNS metastasis at first relapse (patients, %) 39/217 (18%)
Unique first site metastasis 31/217 (14.3%)
Carcinomatous meningitis 28/216 (13%)
CNS metastasis as secondary site (associated with other metastases) 167/218 (76.6%)
Other main metastatic sites at CNS metastasis diagnosis (n = 180)
Bone 111/178 (62.4%)
Lung/pleura 86/178 (48.3%)
Lymph nodes 101/178 (56.7%)
Liver 34/178 (19.1%)
Median interval between CNS metastasis and other metastases 5.5 months (0.1-29)
Survival following CNS metastasis
Median survival for study population (months, range) 13.1 months (11-15.8)
Median survival for CNS metastasis as first site of relapse 14.2 months (10.6-22.2)
Median survival for secondary CNS metastasis (associated with other metastases) 13 months (10.5-15.8)
Death at 2 years (Kaplan-Meier estimate) 70.27
Median time to GPA threshold 1-2/2.5-3/3.5-4 patients
Score 1 - 2 10 months
Score 2.5 - 3 12 months
Score 3.5 - 4 24 months
*Data was missing for some patients. BC: breast cancer; CNS: central nervous system; GPA: Graded Prognostic Assessment.
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a new treatment regimen) of chemotherapy was intro-
duced. Up to seven lines of cytotoxic chemotherapy
(median: two lines) were given in 185 patients (84.8%)
after diagnosis of CNS metastasis. Use of trastuzumab
or lapatinib-based therapy decreased from 83.4% for
patients on first-line treatment (N = 175) to 48.1% for
patients on their fifth line of treatment or more (N = 27).Trastuzumab was most frequently used as a first-line
therapy and lapatinib as a second-line therapy. Chemo-
therapy was mainly delivered during outpatient hospital-
isation. Radiotherapy was administered to 200 patients
(91.7%), and included whole brain radiotherapy (77.3%),
stereotactic radiosurgery (9.6%) or both (6%). Patients re-
ceived one course of radiotherapy (86.8%), two courses of






















Figure 1 Overall survival from diagnosis of CNS metastases. Black: patients with brain metastases as first relapse; blue: patients with
secondary metastases.
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patient was ten. Radiation therapy sessions were deliv-
ered on an outpatient hospitalisation for 80% (177/229
treatments) and during inpatient admission for 22.7%
(52/229) with a median length of stay of thirteen days.Table 2 Health-care resources used after diagnosis of CNS dia
Chemotherapy including targeted therapy
Use of trastuzumab- or lapatinib- based therapies Trast
1st line (n = 175) 118
2nd line (n = 127) 63
3rd line (n = 81) 39
4th line (n = 48) 23
5th line and more (n = 27) 7 (
Radiotherapy
Whole brain radiotherapy only
1 cycle radiotherapy
2 cycles radiotherapy (SRS boost or EBRT)
Second SRS
SRS only
Both (whole-brain radiotherapy and SRS)
Whole-brain radiotherapy 2D
Whole-brain radiotherapy 3D
Median fractions per patient
Neurosurgery
Emergency unit visits
Mean length of stay
Median length of hospital stay (days, range)
Mean number of complications leading to hospitalisation
Data are presented as number of patients (%). EBRT: external beam radiotherapy; SNeurosurgery was performed in only 29 patients (13.3%)
and the median duration of inpatient admission was seven
days. 72.9% (159/218) of patients required an emergency
visit at least once during the follow-up period. Patients
had 1 to 10 hospital stays either in the index hospitalgnosis
185/218 (84.8%)
uzumab Lapatinib Both All
(67.4%) 26 (14.9%) 2 (1.1%) 146 (83.4%)
(49.6%) 34 (26.8%) 1 (0.8%) 98 (77.2%)
(48.1%) 15 (18.5%) 2 (2.5%) 56 (69.1%)
(47.9%) 9 (18.8%) 2 (4.2%) 34 (70.9%)













14.9 days (95% - CI 13.2-16.7)
9 days (range 1–221)
0.44 (95/218)
RS: stereotactic radiosurgery; 2D: two-dimensional; 3D: three dimensional.
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establishment. The median length of stay was nine days.Health care costs
Health care costs decreased during the two-year follow-
up period, while cost variability increased (Table 3), with
the majority of costs concentrated within the first year
of management of metastatic disease. The estimated
mean treatment cost of HER2-positive BC with CNS
metastases was €35,735 per patient [95% CI, 31,716 to
39,898] in the first year following diagnosis of CNS me-
tastasis and €28,939 [95% CI, 22,540 to 35,722] in the
second year. Health care costs between patients with
CNS metastases as first site of relapse and patients with
secondary CNS metastases did not differ significantly at
one year after diagnosis of CNS metastasis (€37,284 vs.
€35,246, p = 0.73). The distribution of costs by type of
resource use is presented in Figure 2 for patients with
CNS metastases as first site of relapse and patients with
secondary CNS metastases. The proportion of costs at-
tributed to inpatient hospitalisations was similar to those
attributed to expensive drugs irrespective of follow-up
duration (€18,135 per patient for hospitalisations vs.
€17,599 per patient for expensive drugs after one year of
follow-up; corresponding to 50.8% and 49.2% of total
costs respectively). Medical care and palliative care were
the largest cost drivers contributing to 55% of the total
inpatient admission cost while chemotherapy and radi-
ation therapy contributed to 35% and 10% of the in-
patient admission costs respectively.Discussion and conclusions
This retrospective observational study has described
treatment patterns, survival and health care resource
utilisation for 200 HER2-positive BC patients with CNS
metastases treated in ten representative French cancer
centres. The clinical characteristics of the observed pa-
tients are consistent with those of recently published
series on HER2-positive BC with CNS metastases in
terms of metastasis characteristics, overall survival from
metastatic BC diagnosis, time from metastatic BC diag-
nosis to development of CNS metastases and treatments
after diagnosis of CNS metastases [5,24].Table 3 Total mean cost and kaplan-meier estimate per 6-mo
First site of relapse
Kaplan-Meier estimate (%) Mean cost (€) [95 CI%
(bootstrap)]
0-6 months 78.4% 20 227.39 [15 514.81; 25 34
7-12 months 56.6% 18 103.14 [12 747.91; 23 71
13-18 months 42.4% 19 173.93 [11 648.09; 27 51
19-24 months 36.2% 14 376.70 [7 348.29; 22 56In our study, costs were assessed by site of relapse (CNS
metastasis as first relapse or CNS metastasis as secondary
site, associated with other metastases). We also considered
the line of cytotoxic therapy and the use of targeted ther-
apies specific for HER2. The most frequent treatment ap-
proach offered to patients with HER2-positive BC with
CNS metastases in this population was chemotherapy,
followed by radiotherapy. Chemotherapy was the most
important source of cost, comparable to hospitalisation
costs. The weight of chemotherapy in expenditure for BC
patients underlines the importance of further clinical re-
search to identify the most effective chemotherapeutic
treatment regimens for this population of patients. Given
the diversity of treatment strategies used in BC with CNS
metastases, and our findings showing that chemotherapy
is both costly and frequently associated with poor clinical
outcome, it seems important to test and validate differ-
ent treatment algorithms under real-world conditions.
This would provide a better estimate of the relative
cost-effectiveness of different treatment options for BC
with CNS metastases.
In addition, the poor outcomes and high treatment
costs observed in these BC patients with CNS metasta-
ses suggest a need to diagnose and treat these metastases
as early as possible, and before neurological signs appear,
in order to optimise the chances of therapeutic success.
However, more proactive screening for CNS metastases
and earlier treatment may paradoxically generate higher
costs of care due to improved life expectancy and longer
duration of therapy. Such increased costs would, how-
ever, be expected to be partially offset by a better quality
of life. Specialist care structures for patients with CNS me-
tastases would also be useful in order to teach patients to
recognise and cope with neurological complications with
the goal of improving quality of life for patients and their
entourage and of limiting emergency department visits
and hospitalisations.
We found that the mean cost in the first year following
diagnosis was 35,735€ per patient [95% CI: 31,716-39,898].
This estimate appears to be in the same range as those re-
ported in previously published studies, although compari-
sons should be interpreted with caution due to potential
differences in the study population, the range of costs con-
sidered and the method of analysis. A small retrospectiventh period (2 years follow-up)
Secondary site
Kaplan-Meier estimate (%) Mean cost (€) [95 CI%
(bootstrap)]
2.19] 74.0% 19 141.01 [16 885.80; 21 401.47]
2.83] 52.1% 17 150.03 [14 187.45; 20 139.93]
0.13] 37.1% 14 125.19 [10 996.51; 17 530.20]
4.50] 27.7% 14 774.77 [10 117.74; 20 096.10]
Figure 2 Distribution of medical costs of patients with CNS metastases over the two year follow-up period. Open columns: patients with
brain metastases as first relapse; filled columns: patients with secondary metastases. Percentages are calculated with respect to total direct
medical costs.
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France [25] reported total per-patient direct yearly costs
from diagnosis to first metastatic progression of €39,607
for those patients who received trastuzumab. Data from a
single-centre, retrospective, observational study of 131
HER2-positive metastatic BC patients receiving trastuzu-
mab in France reported overall annual direct costs per
year of €47,832, costs being driven primarily by the
costs of trastuzumab (44%) and hospitalisation (41%)
[26]. Data from Sweden also indicate that patients with
HER2-positive tumours incur higher cost than HER2-
negative patients, probably due to the higher cost of tar-
geted therapies, and also to radiotherapy [16].
Further information on the costs of metastatic BC is
available from insurance claims databases. A recent French
national database analysis estimated the mean annual cost
of BC with brain metastases at €29,995 per patient treated
with trastuzumab, and assumed to be HER2-positive [27].
In a database analysis from the USA, the direct costs of
brain metastases secondary to BC, included medication,
outpatient care and inpatient admissions were US$60,045
(€50,898) at six months and US$99,899 (€84,681) at
12 months (2006) [28]. The mean total cost for BC patients
with brain metastases was more than twice that of patients
without brain metastases at 6 and 12 months.
Although claims database analyses enable broad and
exhaustive estimates of cost of illness at a national level
to be made relatively rapidly and easily, they are less
powerful for comparing sub-groups of populations and
for matching economic data to clinical outcomes at the
individual patient level. In this respect, observational co-
hort studies present a number of advantages. Although
such studies may be time-consuming and require sub-
stantial investment of resources, they provide accurate
and detailed information on health care consumption atan individual patient level in both hospital and commu-
nity settings, and allow the reconstitution of the entire
healthcare trajectory of individual patient to be reconsti-
tuted. Moreover, cohort analyses provide information on
costs in relation to survival and other clinical endpoints.
In particular, the influence of potentially different progno-
sis between sub-groups on health-care consumption can
be assessed. Such data are important to collect in order to
refine modelling studies of healthcare costs which are crit-
ical to inform decision-making with regard to healthcare
resource allocation. In France, the recent commitment to
including economic assessments into decision-making re-
lating to the drug reimbursement process makes observa-
tional cohort studies particularly relevant.
The findings of this study suggest several avenues for
future research into the management of BC with CNS
metastases in everyday care. These include comparison
of costs and outcomes associated with different treatment
strategies, which may well not be the same in everyday care
than in clinical trials where patients are selected and treat-
ment adherence is optimized. Moreover, the economic and
clinical implications of early detection of CNS metastases
also need to be evaluated. In addition, it would be of inter-
est to investigate patient-and disease- related determinants
of cost and outcome in BC with CNS metastases.
This study has a number of limitations, notably those
common to all retrospective observational studies. In
particular, the method of selecting patients on the basis
of ICD codes may not have allowed exhaustive recruit-
ment due to incomplete or erroneous information in the
patient records. We also limited our study to treatments
received in the treating centre, which may have led to an
underestimation of total costs. In particular, we noticed
that surgical interventions were not often performed in
the treating centre and are thus not included in the cost
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handle cost-censored data using the Kaplan-Meier esti-
mator, which may introduce error due to the presence of
outliers. This is because the weight attributed to patients
incurring very high or low costs will increase over the
follow-up period, assuming that they survive.
Our analysis is limited to direct medical costs viewed
from the health insurance perspective. Information on
non-medical costs such as ambulance transportation and
indirect costs such as loss of productivity were not col-
lected since they are not documented in the patient
records. Moreover, information on loss of productivity
related to sick leave is difficult to collect retrospectively.
In many cases, patients with metastatic BC have to stop
working altogether. Previous studies have estimated that
direct medical costs constitute only about 40% of the
total societal cost of these patients [16,17,29].
In conclusion, this study documents the use of a range
of individualised disease management strategies in a na-
tional cohort of HER2-positive BC patients with CNS
metastases. Expensive targeted therapies and cytotoxic
agents appear to be the main cost drivers, together with
hospitalisation costs. Identifying cost drivers may help
optimise healthcare expenditure and inform the develop-
ment of cost-effective therapeutic strategies.
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